The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world, and, in 1971, it became one of the nation’s first National Cancer Institute (NCI)-designated comprehensive cancer centers. MD Anderson is No. 1 for cancer in U.S. News & World Report’s “Best Hospitals” rankings and has been named one of the nation’s top two hospitals for cancer since the rankings began in 1990.

Through integrated and comprehensive programs, MD Anderson advances transformative discovery, prevention, translational and clinical research. We aim to provide a deeper understanding of all cancer types, including rare cancers not often studied or treated elsewhere, to ultimately lead to meaningful benefits for patients and society. In fiscal year 2024, MD Anderson invested $1.3 billion in research efforts. MD Anderson also is home to world’s largest oncology clinical trials program, with more than 1,500 ongoing trials in FY24, and 27 drugs tested at MD Anderson received FDA approval in FY24.

Through partnership with our patients, our scientists and clinicians seamlessly collaborate to develop breakthroughs that transform the field. Discoveries from our labs are swiftly translated into new therapies in the clinic, and insights from the clinic inform our laboratory work in real time. At every step, a rapidly growing team of data scientists provide insights, processes and tools that better inform and accelerate studies. Our culture of collaboration provides early-career researchers accessible mentorship and hands-on training from some of the most brilliant minds in the world across the spectrum of cancer research and care.

Latest from The University of Texas MD Anderson Cancer Center


Durvalumab-Based Treatment Before and After Surgery Improves EFS in Early-Stage NSCLC

March 09, 2023

Durvalumab plus neoadjuvant chemotherapy followed by surgery and adjuvant single-agent durvalumab significantly improved event-free survival vs neoadjuvant chemotherapy and surgery alone in patients with resectable stage IIA-IIIB non–small cell lung cancer.

New Generation of TKIs Challenge Standards of Care in Newly Diagnosed Ph+ ALL

March 07, 2023

The advent of effective first-generation TKIs has allowed for improvements among patients with Philadelphia chromosome–positive disease, which is traditionally associated with a poor prognosis, as it generally does not respond to conventional chemotherapy options.

Wang Details Caveats to Standards of Care for Treating Patients With MCL

February 28, 2023

When treating patients with mantle cell lymphoma, early identification and appropriate frontline therapy remains critical, and therapies may vary for those 65 years and older compared with patients under the age of 65, with several additional factors also having a role in approaching treatment options for a new patient in the clinic.

Real-World Analysis May Clarify Role of Adjuvant Endocrine Therapy in Premenopausal HER2+ Breast Cancer

February 24, 2023

Jasmine Sukumar, MD, discusses the purpose of analyzing endocrine therapy use in HR-positive/HER2-positive patients, key data presented from the retrospective analysis at SABCS, and the need for improved understanding of clinical indications for endocrine therapy in this breast cancer subtype.